Navigation Links
Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
Date:2/12/2008

BETHESDA, Md., Feb. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the publication of a comprehensive review article entitled, "BiTE: A new class of antibodies that recruit T cells" in the journal Drugs of the Future. BiTE(R) antibodies are designed to activate the body's T cells to seek and destroy cancer cells in a tightly controlled manner.

The review article discusses recently published preclinical and clinical data on BiTE antibodies, which are evolving into a new class of antibody-based therapeutics, with several new members in various stages of development. One emphasis is on CD19-specific BiTE antibody MT103 (also known as MEDI-538), which produced complete and partial responses at generally well tolerated and very low doses in late-stage lymphoma patients. Another emphasis is on several preclinical studies showing significant anti-tumor activity of three other BiTE antibodies targeting solid tumors by EpCAM (CD326), EphA2 or CEA antigens. All three tumor-associated antigens are found on many solid tumors. In addition, the article provides a detailed description of the mode of action of BiTE antibodies, comparing it to natural T-cell responses.

"Our latest review article demonstrates the clinical progress and high level of scientific understanding the company has acquired in numerous published studies about its proprietary BiTE antibody technology," commented Patrick A. Baeuerle, Micromet's chief scientific officer. "BiTE antibodies represent a novel platform of clinically-validated, antibody-based therapeutics for the treatment of a wide range of cancers
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
3. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
4. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
5. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
6. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
7. Inverseon Announces Positive Phase IIa Asthma Study
8. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
9. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- This is a professional ... Heparin sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) ... of Heparin sodium (CAS 9041-08-1) & calcium (CAS ... The report then explores global and China,s top ... (CAS 37270-89-6) listing their product specification, capacity, production ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/30/2014)... California , July 30, 2014 ... technology and CUDA programming expertise to big data, ... markets  eInfochips, a leading engineering R&D ... clients to develop NVIDIA GPU-powered solutions for ... high-performance computing (HPC), industrial , ...
Breaking Medicine Technology:Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2eInfochips to Develop NVIDIA GPU-powered Solutions for Aerospace and Defense, Medical Imaging, HPC and Visual Computing 2
... Reportlinker.com announces that a new market research ... Pharmaceuticals: Global Industry Guide ... Pharmaceuticals: Global Industry Guide is ... analysis covering the Pharmaceuticals industry. It includes ...
... 2012 Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE ... three lead drugs (Zertane™ completed two phase ... licensing distribution of these drugs and engaged in further ... interim review of the first 50% of patients enrolled ...
Cached Medicine Technology:Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 2Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 3Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule 4
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... sub-Saharan Africa is being revitalized and expanded through ... broadening curricula, upgrading Internet access and providing cutting-edge ... the first substantial publication by participants of the ... than 225 authors detailed progress being made at ... supplement being published today by the journal ...
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... cancer as well as evolutionary changes in a living ... randomly throughout the genome. , However, recent studies have ... multiple mutations that arise simultaneously and in close proximity ... frequently found in regions where chromosomal rearrangements take place. ... Reports , may one day lead to new cancer ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2
... macular degeneration, also called juvenile macular degeneration, is an ... This condition results from a defect in the ABCR ... that removes all-trans-retinaldehyde, a vision byproduct, from retinal rods ... epithelium (RPE), a layer of cells near the retina. ...
... inflammatory condition of the bladder wall. It typically affects ... men. Investigators are testing the bacteria Bacillus Calmette-Guerin(BCG), which ... treating interstitial cystitis, by inserting six installations into the ... study of BCG// also showed that 60 percent of ...
... a screening of the colon do not go through ... procedure that is currently available involves inserting a flexible ... requires anaesthesia and there's a remote chance that the ... patients now have an easier option with the discovery ...
... worldwide and its incidence is high in the Asian and ... foodstuffs. The cancer is also becoming prevalent in the United ... gene activity in liver tumors using the new 'gene chip' ... They found that there is a difference between// those tumors ...
... has shown that infants born during night time have ... to those born during day time. Previous studies have ... weekends and holidays have an increased risk of death ... experienced staff for better obstetric and neonatal care during ...
... Vitamin C has been believed, over the years, to be a ... proved to be true by researchers who have studied changes in ... their study of 12 healthy subjects who took one gram of ... immune system response in all of them during the period. Their ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: